FGF19 and metabolic dysfunction-associated steatotic liver disease: Furthermore, the circulating FGF19 concentration is reduced in patients with NAFLD/NASH [110,111], suggesting that dysregulated FGF19 expression might contribute to the pathogenesis of NAFLD/NASH.